RecruitingNCT07598422
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
Specified Use-Results Study of ILARIS Solution for S.C. Injection (Schnitzler's Syndrome)
Sponsor
Novartis Pharmaceuticals
Enrollment
10 participants
Start Date
May 13, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.
Eligibility
Min Age: 0 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with schnitzler syndrome. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 0 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07598422